The Efficacy Study of Aclasta (Zoledronic Acid 5mg) on Prosthetic Fixation in Postmenopausal Women After Cementless Total Hip Arthroplasty (THA): a 24 Months, Single Center, Open- Label, Randomized, Parallel Controlled Study

Trial Profile

The Efficacy Study of Aclasta (Zoledronic Acid 5mg) on Prosthetic Fixation in Postmenopausal Women After Cementless Total Hip Arthroplasty (THA): a 24 Months, Single Center, Open- Label, Randomized, Parallel Controlled Study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 02 Feb 2016 Planned End Date changed from 1 Aug 2019 to 1 Jan 2020 as reported by ClinicalTrials.gov record.
    • 02 Feb 2016 Planned primary completion date changed from 1 Aug 2019 to 1 Jan 2020 as reported by ClinicalTrials.gov record.
    • 02 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top